ESMO 2025 Highlights Major Advances in Breast Cancer Treatment Across All Subtypes
核心洞察
CDK4/6 (搜索) inhibitors are establishing new standards in early-stage HR+ breast cancer (搜索), with abemaciclib and ribociclib showing significant improvements in disease-free survival in adjuvant settings.
The second-line HR+ metastatic setting has become highly fragmented with multiple targeted therapies, including oral SERDs like giredestrant showing 44-62% reduction in disease progression risk.
Triple-negative breast cancer (搜索) treatment paradigm is shifting with TROP2 (搜索)-directed ADCs, as sacituzumab govitecan and datopotamab deruxtecan demonstrate substantial survival benefits in first-line metastatic disease.
ESMO 2025 showcased significant advances across all breast cancer (搜索) subtypes, addressing critical gaps in treatment sequencing, resistance mechanisms, and patient outcomes. The conference highlighted how targeted combinations and biomarker-driven strategies are reshaping clinical practice for hormone receptor-positive (HR+), HER2 (搜索)-positive, and triple-negative breast cancer (搜索) (TNBC).
CDK4/6 Inhibitors Redefine Early-Stage Management
Adjuvant CDK4/6 (搜索) inhibition has emerged as a cornerstone for high-risk HR+ early-stage disease. The monarchE study demonstrated that adding abemaciclib to endocrine therapy significantly improved invasive disease-free and distant relapse-free survival, with dose reductions not compromising clinical benefit. The NATALEE trial further expanded this approach, suggesting ribociclib may reduce recurrence risk across a broader patient population.
Next-generation agents are addressing resistance mechanisms through novel approaches. Pfizer's atirmociclib offers CDK4 (搜索)-selective inhibition, while their KAT6 (搜索) inhibitor PF07248144 produced a 37% response rate and median progression-free survival (PFS) of 10.7 months. Olema's OP3136 demonstrated preclinical synergy with CDK4/6 (搜索) blockade, representing another promising avenue for overcoming resistance.
Second-Line HR+ Setting Becomes Increasingly Complex
The second-line HR+ metastatic landscape has fragmented into multiple targeted niches as resistance to first-line CDK4/6 (搜索) inhibition emerges through RB1 (搜索) loss, CDK4 (搜索) amplification, and kinase mutations. Multiple regimens have gained approval based on trials including CAPITELLO-291, OlympiaD, EMERALD, BOLERO-2, and SOLAR-1.
The Phase 3 evERA trial marked a significant milestone, with giredestrant plus everolimus significantly improving PFS versus fulvestrant plus everolimus. Giredestrant reduced the risk of disease progression or death by 44% in the intention-to-treat population and 62% in ESR1 (搜索)-mutated patients.
Dual PI3K (搜索)/ESR1m inhibition showed promise in VIKTORIA-1, where gedatolisib plus fulvestrant with or without palbociclib reduced progression risk by approximately 70% and extended median PFS to 7.4-9.3 months. The ReDiscover-2 trial demonstrated that RLY2608, a mutant-selective PI3Kα inhibitor, delivered a median PFS of 10.3 months and 38.7% response rate with fulvestrant.
TROP2 (搜索)-directed antibody-drug conjugates (ADCs) represent another emerging strategy. Sacituzumab tirumotecan showed statistically significant improvement in median PFS (HR 0.35) in the China-only Phase 3 OptiTROPBreast02 trial, comparing favorably to chemotherapy in previously treated HR+/HER2 (搜索)- metastatic breast cancer (搜索).
TNBC Treatment Paradigm Shifts with Immunotherapy and ADCs
Triple-negative breast cancer (搜索) has seen dramatic advances through immunotherapy and ADC combinations. Gilead's sacituzumab govitecan remains the second-line standard, but ESMO 2025 data from ASCENT-03 (PD-L1-negative) and ASCENT-04 (PD-L1-positive) positioned it as a potential first-line standard as well.
Datopotamab deruxtecan achieved a remarkable 5-month overall survival improvement in first-line TNBC in the TROPION-Breast02 trial, representing an unprecedented benefit in this aggressive disease subtype. These results highlight the transformative potential of TROP2 (搜索)-directed therapies in TNBC, where high TROP2 expression correlates with aggressive tumor biology.
HER2+ Disease Advances Through ADC Innovation
The HER2 (搜索)+ landscape continues evolving with ADC leadership. The DESTINY-Breast09 trial showed trastuzumab deruxtecan significantly improved progression-free survival compared with the historic THP regimen in first-line treatment, with approximately 70% of patients remaining progression-free at two years.
This success extends across disease stages. DESTINY-Breast11 demonstrated a pathological complete response rate of 67.3% in the neoadjuvant setting, while DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death risk in the adjuvant setting.
For HR+/HER2 (搜索)+ metastatic disease, the PATINA trial revealed that maintenance palbociclib plus anti-HER2 therapy plus endocrine therapy extended median PFS to 44.3 months versus 29.1 months, with patient-reported outcomes data confirming a favorable risk-benefit ratio.
Future Challenges and Opportunities
As the therapeutic arsenal expands, oncologists face increasing complexity in treatment sequencing decisions. Serial biomarker testing through tissue biopsy, liquid biopsy, or circulating tumor DNA will likely become integral for detecting resistance mutations and guiding treatment transitions.
Critical questions remain regarding optimal sequencing of CDK4/6 (搜索) inhibitors, SERDs, PI3K (搜索)/AKT/mTOR inhibitors, and ADCs. The potential for CDK4 (搜索)-selective agents or KAT6 (搜索) inhibitors to delay resistance requires further investigation, as does balancing efficacy with cost and quality of life considerations.
Next-generation SERDs and complete estrogen receptor antagonists may eventually challenge aromatase inhibitors or tamoxifen in adjuvant settings, though this faces significant hurdles given the established long-term safety, efficacy, and affordability of existing endocrine therapies.
Mutant-selective PI3K (搜索) inhibitors designed to reduce adverse events like hyperglycemia represent progress, but high drug costs may limit real-world adoption without substantial survival benefits. Ensuring equitable access to these complex regimens across healthcare systems remains essential for translating clinical trial successes into improved patient outcomes.